Screening for cancer: Future potential

European Journal of Cancer

Volumn 35, Issue 14, 1999, Pages 1925-1932

  Cuzick, J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Cancer screening; Cervical cancer; Colorectal cancer; Cytology; Human papillomavirus; Mammography; Ovarian cancer; Prostate cancer; Sigmoidoscopy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CYTOLOGY; DIAGNOSTIC ACCURACY; HUMAN; LUNG CANCER; MAMMOGRAPHY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGMOIDOSCOPY; STOMACH CANCER; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0033385556     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00295-6     Document Type: Article

References (53)

1. Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In Magnus K, ed. Trends in Cancer Incidence: Causes and Practical Implications. Washington, U.S.A., Hemisphere Publishing Corporation, 1982, 279-292.
2. Läärä E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, i (30 May), 1247-1249.
3. Sasieni P., Cuzick J., Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet. 346:1995;1566-1567.
4. Banda-Gamboa H., Ricketts I., Cairns A., Hussein K., Tucker J.H., Husain N. Automation in cervical cytology: an overview. Anal. Cell. Pathol. 4:1998;25-48.
5. Williams G.H., Romanowski P., Morris L.et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc. Natl. Acad. Sci. 95:1998;14932-14937.
6. Reid R, Greenberg MD, Lorincz A, et al. Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection? Am J Obstet Gynecol 1991, 164, 1461-1469; 1469-1471.
7. Cuzick J., Szarewski A., Terry G.et al. Human papillomavirus testing in primary cervical screening. Lancet. 345:1995;1533-1536.
8. Schneider A., Zahm D.M., Kirchmayr R.et al. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am. J. Obstet. Gynecol. 174:1996;1534-1541.
9. Ratnam S, Prafull G, Franco E, Ferenczy A. Utility of HPV testing in combination with Papanicolaou smear in primary cervical screening. 17th International Papillomavirus Conference, January 9-15 1999, Charleston, South Carolina, U.S.A.
10. Cuzick J., Terry G., Ho L., Hollingsworth T., Anderson M. Human papillomavirus type IL DNA in cervical smears as a predictor of high grade cervical intraepithelial neoplasia. Lancet. 339:1992;959-960.
11. Elfgren K., Bistoletti P., Dillner L.et al. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am. J. Obstet. Gynecol. 174:1996;937-942.
12. Bollen L.J.M., Tjong-A-Hung S.P., van der Velden J.et al. Human papillomavirus DNA after treatment of cervical dysplasia: low prevalence in normal cytologic smears. Cancer. 77:1996;2538-2543.
13. Nyström L., Rutqvist L.E., Wall S., Lindgren A., Lindqvist M., Rydén S.et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 341:1993;973-978.
14. Falun Organising Committee. Breast cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996, 68, 693-699.
15. Bjurstam N., Bjorneld L., Duffy S.W.et al. The Gothenburg Breast Screening Trial. Cancer. 80:1997;2091-2099.
16. Cuzick J., Holland R., Barth V.et al. Electropotential measurements as a new modality for breast cancer diagnosis: results from a multicentre trial. Lancet. 352:1998;359-363.
17. Morimoto T., Knouchi Y., Iritani T., Kimura S., Konishi Y., Mitsuyama N. Measurement of the electrical bio-impedance of breast tumors. Eur. Surg. Res. 22:1990;86-92.
18. Simpson H.W., Griffiths K., McArdle C., Paulson A.W., Hume P., Turkes A. The luteal heat cycle of the breast in health. Breast Cancer Res. Treat. 27:1993;239-245.
19. Coppleson M., Reid B.L., Skladnev V.N., Dalrymple J.C. An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe. Int. J. Gynecol. Cancer. 4:1994;79-83.
20. Mandel J.S., Bond J.H., Church T.R.et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med. 328:1993;1365-1371.
21. Hardcastle J.D., Chamberlain J.O., Robinson M.H.E.et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 348:1996;1472-1477.
22. Kronberg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 348:1996;1467-1471.
23. Faivre J., Tazi M.A., El Mrini T., Lejeune C., Benhamiche A.M., Dassonville F. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Br. J. Cancer. 79:1999;680-683.
24. Ahlquist D.A., Wieand H.S., Moertel C.G.et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA. 269:1993;1262-1267.
25. St John D.J.B., Young G.P., Alexeyeff M.A.et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 104:1993;1661-1668.
26. Morson B.C. Genesis of colorectal cancer. Gastroenterology. 5:1976;505-525.
27. Selby J.V., Friedman G.D., Quesenberry C.P., Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 326:1992;653-657.
28. Newcomb P.A., Norfleet R.G., Storer B.E., Surawicz T.S., Marcus P.M. Screening sigmoidoscopy and colorectal cancer morality. J. Natl. Clin. Inst. 84:1992;1572-1575.
29. Müller A.D., Sonnenberg A. Protection by endoscopy against death from colorectal cancer: a case-control study among veterans. Arch. Intern. Med. 155:1983;1741-1748.
30. Atkin W.S., Cuzick J., Northover J.M.A., Whynes D.K. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 341:1993;736-740.
31. Breslow N., Chan C.W., Dhom G.et al. Latent carcinoma of prostate at autopsy in seven areas. Int. J. Cancer. 20:1977;680-688.
32. Bentvelsen F.M., Schroder F.H. Modalities available for screening for prostate cancer. Eur. J. Cancer. 29A:1993;804-811.
33. Campbell S., Bhan V., Royston P., Whitehead M.I., Collins W.P. Transabdominal ultrasound screening for early ovarian cancer. Br. Med. J. 299:1989;1363-1367.
34. Bourne T.H., Campbell S., Reynolds K.M.et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br. Med. J. 306:1993;1025-1029.
35. Jacobs I., Davies A.P., Bridges J.et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br. Med. J. 306:1993;1030-1034.
36. Bourne T.H., Campbell S., Reynolds K.et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecologic. Oncol. 52:1994;379-385.
37. Prorok PC, Byar DP, Smart CR, Baker SG, Connor RJ. Evaluation of screening for prostate, lung, and colorectal cancers: the PLC Trial. In Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge University Press, New York, 1976, 300-320.
38. Hisamichi S, Fukao A, Sugawara N, et al. Evaluation of mass screening programme for stomach cancer in Japan. In Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge University Press, New York, 1991, 357-370.
39. De Koster E., Buset M., Nyst J.-F., Deltenre M. Gastric screening prospects. Eur. J. Cancer Prev. 2:1993;263-268.
40. Sun T, Yu H, Hsia C, Wang N, Huang X. Evaluation of sero-survey trials for the early detection of hepatocellular carcinoma in area of high prevalence. In Chamberlain J, Miller AB. Screening for Gastrointestinal Cancer. Bern, Hans Huber, 1988, 81-86.
41. Shen Q., Liu S.F., Dawsey Cao J.et al. Cytologic screening for esophageal cancer: results from 12,877 subjects from a high-risk population in China. Int. J. Cancer. 54:1993;185-188.
42. Chen J.Y., Chen C.J., Liu M.Y.et al. Antibody to Epstein-Barr virus-specific Dnase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J. Med. Virol. 27:1989;269-273.
43. Sawada T, Matsumura T, Matsuda Y, Kawakatsu H. Neuroblastoma: studies in Japan. In Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge University Press, New York, 1991, 325-336.
44. Sawada T. Past and future of neuroblastoma screening in Japan. Am. J. Pediatr. Hematol. Oncol. 14:1992;320-326.
45. Murphy S.B., Cohn S.L., Craft A.W.et al. Do children benefit from mass screening for neuroblastoma? Lancet. 337:1991;344-345.
46. Womack SD, Chirenje ZM, Blumenthal PD, et al. Evaluation of Hybrid Capture II, probe-B assay in cervical cancer screening of women in Zimbabwe, Africa. In Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath J, Chipato T, Ngwalle E, Shah KV, eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 285.
47. Gurley M, Carter CD, Bounassif S, Laverty CRA, Tabrizi SN, Garland SM. Does HPV status have a role in the management of women with abnormal cervical cytology? In Gurley M, Carter CD, Bounassif S, Laverty CRA, Tabrizi SN, Garland SM, eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 288.
48. Clavel C, Masure M, Bory J-P, et al. Human papillomavirus detection by the hybrid capture II assay is a sensitive test to detect in routine high grade cervcial lesion. In Clavel C, Masure M, Bory J-P, et al., eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 170.
49. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. In Cuzick J, Beverley E, Ho L, et al., eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 98.
50. Gilbertsen V.A., Nelms J.M. The prevention of invasive cancer of the rectum. Cancer. 41:1978;1137.
51. Friedman G.D., Collen M.F., Fireman B.H. Multiphasic health check-up evaluation: a 16-year follow-up. J. Chron. Dis. 39:1986;453-463.
52. Atkin W.S., Morson B.C., Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N. Engl. J. Med. 326:1992;658-662.
53. Winawer S.J., Zauber A.G., Ho M.N.et al. Prevention of colorectal cancer by colonoscopic polypectomy. N. Engl. J. Med. 329:1993;1977-1981.